Bradmer Pharmaceuticals is a biotechnology company focused on the development and commercialization of new and innovative cancer therapies. Bradmer’s lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer. To date, over US$60 million has been spent on research and development of the licensed treatment, which has been used in over 160 patients with excellent results and has completed Phase II clinical trials conducted by researchers at Duke University. Bradmer is currently in the process of organizing a multi-center clinical trial of the licensed treatment. Neuradiab was recently granted Orphan Drug Status by the U.S. Food and Drug Administration.
Video from: clipsyndicate.com
